Description: Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. It also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic, cardiology, dermatology, diabetes, fever, gastroenterology, hematology, helminthics, hepatoprotective, immunosuppressant, infectious disease, malarial, neurology, nutraceuticals, ophthalmology, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology, as well as products in various dosage forms comprising oral solids, powders for suspension, and liquid and dry injections. The company exports its products to approximately 100 countries worldwide. It has an agreement with Medicines for Malaria Venture to develop a novel antimalarial co-formulation named Atoguanil. The company was incorporated in 1949 and is based in Mumbai, India.
Home Page: www.ipca.com
125, Kandivli Industrial Estate
Mumbai,
400067
India
Phone:
91 22 6210 5000
Officers
| Name | Title |
|---|---|
| Mr. Premchand Godha | Chairman, CEO & MD |
| Mr. Ajit Kumar Bhanwarlal Jain | CFO, Joint MD & Exec. Director |
| Mr. Harish P. Kamath | Compliance Officer, Corp. Counsel & Company Sec. |
| Mr. Pranay Godha | Exec. Director |
| Mr. Prashant P. Godha | Exec. Director |
| Mr. Pawan Kothari | VP of Operations |
| Mr. Vishnu Saran Singh Kushwaha | VP of Technical |
| Mr. Sunil Ghai | Pres of Marketing |
| Mr. Sameer S. Tamhane | Sr. VP of HR |
| Dr. Ashok Kumar | Pres of R&D - Chemicals |
Exchange: BSE
Country: IN : India
Currency: Indian Rupee (INR)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 17.9753 |
| Price-to-Book MRQ: | 3.7935 |
| Price-to-Sales TTM: | 3.7514 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |